Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Journal: Oncotarget

Published: March 12, 2025

Abstract

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.

Authors

Wafik El Deiry, Catherine Bresson, Fanny Wunder, Benedito Carneiro, Don Dizon, Jeremy Warner, Stephanie Graff, Christopher Azzoli, Eric Wong, Liang Cheng, Sendurai Mani, Howard Safran, Casey Williams, Tobias Meissner, Benjamin Solomon, Eitan Rubin, Angel Porgador, Guy Berchem, Pierre Saintigny, Amir Onn, Jair Bar, Raanan Berger, Manon Gantenbein, Zhen Chen, Cristiano De Souza, Rui Manuel Reis, Marina Sekacheva, Andrés Cervantes, William Dahut, Christina Annunziata, Kerri Gober, Khaled Musallam, Humaid Al Shamsi, Ibrahim Abu Gheida, Ramon Salazar, Sewanti Limaye, Adel Aref, Roger Reddel, Mohammed Ussama Homsi, Abdul Rouf, Said Dermime, Jassim Suwaidi, Catalin Vlad, Rares Buiga, Amal Omari, Hikmat Abdel Razeq, Luis Oñate Ocaña, Finn Nielsen, Leah Graham, Jens Rueter, Anthony Joshua, Eugenia Girda, Steven Libutti, Gregory Riedlinger, Mohammed Salem, Carol Farhangfar, Ruben Mesa, Bishoy Faltas, Olivier Elemento, C Pramesh, Manju Sengar, Satoru Aoyama, Sadakatsu Ikeda, Ioana Berindan Neagoe, Himabindu Gaddipati, Mandar Kulkarni, Elisabeth Auzias, Maria Gerogianni, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig, Naftali Frankel, Amanda Ferraro, Jim Palma, Alejandro Gimenez, Alberto Hernando Calvo, Enriqueta Felip, Apostolia Tsimberidou, Roy Herbst, Josep Tabernero, Richard Schilsky, Jia Liu, Yves Lussier, Jacques Raynaud, Gerald Batist, Shai Magidi, Razelle Kurzrock

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Similar Publications